Insulin resistance, blood sugar regulation, metabolic syndrome, and body composition
461 articles
A genomic study of 3,358 biopsy-proven MASLD patients finds APOB pathogenic variants linked to significantly higher steatosis and liver injury scores.
A landmark 500-patient RCT finds sodium bicarbonate offers no benefit over placebo for critically ill adults with metabolic acidosis and shock.
A newly identified protein shields the liver from alcohol injury by bridging mitochondria and fat droplets to enhance fatty acid oxidation.
Takeda's Phase 1 trial evaluates the safety and tolerability of TAK-510, a novel injectable agent targeting nausea and vomiting, across escalating doses.
A systematic review of 10 longitudinal studies finds elevated pancreatic fat strongly predicts future type 2 diabetes and glycemic decline.
Machine learning clusters CGM data into four distinct glycemic patterns, each linked to unique diabetic complication risks.
A landmark RCT shows finerenone reduces eGFR decline and kidney-cardiovascular events in CKD patients without diabetes.
A new review reframes magnesium as a master regulator of mitochondrial energy, metabolic disease, and biological aging.
A global study of 7,040 cirrhosis inpatients finds CKD present in 18% of cases, dramatically worsening outcomes including AKI and mortality.
UCLA researchers outline best practices for respirometry, the gold-standard method for measuring cellular energy and mitochondrial function.
A real-world study of 15,000+ patients finds tirzepatide outperforms both semaglutide and liraglutide in preventing major cardiac events.
Updated review of anti-obesity medications in MASLD finds GLP-1 agonists reduce steatosis and fibrosis, while newer dual/triple agonists show even greater metabolic promise.
